Avior Biotech Company. Inc.

Avior Biotech identifies a valuable problem space in developing organic biological solutions. However, the submission suffers from unrealistic and unsupported claims, such as stating 'most people have used my product' and an audience reach of 'everyone'. The reported 500,000 market cap and a team of 6 indicate an early-stage or small operation rather than widespread adoption. The vagueness of the custom technology and lack of verifiable traction data result in low quality multipliers across the board, placing this project firmly in the minimal traction tier.